Glaukos Corporation
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $7.67B |
| Revenue | $551M |
| Net Income | $-189M |
| Total Assets | $893M |
| Net Assets | $671M |
| Employees | 1,094 |
| Value | |
| P/B | 11.44x |
| P/S | 13.92x |
| FCF Yield | -0.24% |
| Profitability | |
| ROE | -28.22% |
| ROA | -21.19% |
| Op. Margin | -15.58% |
| Revenue Growth | 41.16% |
| Financial Health | |
| Debt Ratio | 33.15% |
| Total Debt | $103M |
| FCF | $-18M |
| Cash | $104M |
| Current Ratio | 5.43x |
| Performance | |
| 1Y Return | 27.64% |
| 1M Return | -6.63% |
| From 52W High | -11.80% |
| 1Y MDD | -30.16% |
| Trading | |
| Volume | 433,424 shares |
| Trading Value | $56M |
| Per Share | |
| EPS | $-3.26 |
| BPS | $11.41 |
Company Info
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.